| |
| |
GLOSSARY
|
| |
Per protocol analysis
|
| |
| |
SPOT ON
|
| |
Surrogate endpoints to evaluate benefit in oncology
|
| |
| |
THERAPY FROM A CRITICAL VIEWPOINT
|
| |
POET-COPD: tiotropium superior to salmeterol
|
| |
| |
a-t READER'S QUESTIONS AND COMMENTS
|
| |
SHIFT study: reevaluation of ivabradine necessary?
UCB: the same with differences
|
| |
| |
IN BRIEF
|
| |
Diuretic strategies for decompensated heart failure
Long-acting risperidone in schizophrenia
Lavender oil (LASEA) and the German Medical Products Advertising Act
Medical journals: influence of funding sources on the content
Cave: vfa brochure - ideal pharmaceutical world for teenagers
|
| |
| |
CURRENT ADR NETWORK REPORT
|
| |
Angioedema due to saxagliptin (ONGLYZA)?
|
 |
Nightmares, depression with dronedarone (MULTAQ)
|
| |
| |
SIDE EFFECTS
|
| |
Increased cardiovascular mortality with olmesartan
|
| |
| |
e a-t IN THE INTERNET
|
| |
Lavender oil (LASEA): Spitzner comments on the a-t article
|
| |